Valneva SE — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $210M

Market Cap: $529.9MPipeline: 46 drugs (24 Phase 3)Patents: 20Founded: 2013Employees: >650HQ: Saint-Herblain, France

Sector Ranking#124 in Biologics / Biosimilars

Overview

Valneva SE is a fully integrated specialty vaccine company with a mission to address unmet medical needs in infectious diseases through prophylactic vaccines. Its strategy combines proprietary technology platforms, including the EB66® cell line, with an end-to-end business model to control development, manufacturing, and commercialization. Key achievements include the launch of the world's only licensed chikungunya vaccine, a commercial portfolio for travel health, and a robust late-stage pipeline featuring a promising Lyme disease vaccine candidate in partnership with Pfizer.

Infectious DiseasesTravel Health

Technology Platform

Valneva's core technology platform includes expertise in live-attenuated and inactivated whole-virus vaccines, supported by its proprietary, high-yield EB66® duck embryo-derived cell line for scalable manufacturing.

Pipeline

46

46 drugs in pipeline24 in Phase 3

Drug	Indication	Stage
IXIARO®- Japanese Encephalitis vaccine	Japanese Encephalitis Vaccine	Approved
IXIARO®	Japanese Encephalitis	Approved
Japanese Encephalitis purified inactivated vaccine	Japanese Encephalitis	Phase 3
IC51 + HAVRIX	Japanese Encephalitis	Phase 3
IXIARO + IXIARO	Japanese Encephalitis	Phase 3

Funding History

3

Total raised:$210M

Debt$80MEuropean Investment BankMay 15, 2020

IPO$110MUndisclosedOct 3, 2013

Series A$20MBpifranceJun 15, 2013

Opportunities

Valneva's primary opportunities lie in the blockbuster potential of its first-in-class chikungunya vaccine in both travel and endemic markets, and the near-term commercialization of its Phase 3 Lyme disease vaccine candidate in partnership with Pfizer, which addresses a massive unmet medical need.

Its integrated platform and broad pipeline provide additional shots on goal in specialty infectious diseases.

Risk Factors

Key risks include commercial execution challenges for its lead asset IXCHIQ®, clinical/regulatory hurdles for its late-stage pipeline, potential future dilution due to capital-intensive R&D, and emerging competition in its core niches from larger pharmaceutical companies.

Competitive Landscape

Valneva competes in travel health with large players like GSK and Sanofi, differentiating through specialized products. In Lyme disease, its partnership with Pfizer makes it the front-runner against other biotech candidates. Its integrated model and EB66® platform provide manufacturing advantages against CDMO-dependent competitors.